Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Warnke, C; Menge, T; Hartung, HP; Racke, MK; Cravens, PD; Bennett, JL; Frohman, EM; Greenberg, BM; Zamvil, SS; Gold, R; Hemmer, B; Kieseier, BC; Stüve, O 
Titel:
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? 
Abstract:
Natalizumab (Tysabri) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, 3 patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with progressive multifocal leukoencephalopathy (PML). The agent was later reapproved and its use restricted to monotherapy in patients with relapsing forms of MS. Since reapproval in 2006, additional cases of PML...    »
 
Zeitschriftentitel:
Arch Neurol 
Jahr:
2010 
Band / Volume:
67 
Heft / Issue:
Seitenangaben Beitrag:
923-30 
Sprache:
eng 
Print-ISSN:
0003-9942 
TUM Einrichtung:
Neurologische Klinik und Poliklinik